Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats

Journal of Hypertension

Volumn 23, Issue 8, 2005, Pages 1525-1530

  Ran, Jianmin ^a   Hirano, Tsutomu ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiosin II; Rat; Receptor; Triglyceride

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; OLMESARTAN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FATTY ACID TRANSPORT; HYPERTENSION; LIPID METABOLISM; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC HYPERTENSION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 23344431676     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000174077.88121.19     Document Type: Article

References (27)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
2. Julius S. Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension. J Cardiovasc Pharmacol 1990; 15 (suppl 5):53-58.
3. Rao RH. Pressor dose of angiotensin II increase hepatic glucose output and decrease insulin sensitivity in rats. J Endocrinol 1996; 148:311-318.
4. Richey JM, Ader M, Moore D, Bergman RN. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol 1999; 277:E920-E926.
5. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40:872-879.
6. Patiag D, Qu X, Gray S, Idris I, Wilkes M, Seale JP. Possible interactions between angiotensin II and insulin: effects on glucose and lipid metabolism in vivo and in vitro. J Endocrinol 2000; 167:525-531.
7. Ran J, Hirano T, Adachi M. Chronic angiotensin II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab 2004; 287:E955-E961.
8. Hennes MM, O'Shaughnessy IM, Kelly TM, LaBelle P, Eagan BM, Kissebah AH. Insulin-resistant lipolysis in abdominally obese hypertensive individuals: role of the renin-angiotensin system. Hypertension 1996; 28:120-126.
9. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138:1512-1519.
10. Okada K, Hirano T, Ran J, Adachi M. Angiotensin II receptor blocker, olmersartan medoxomil, ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 2004; 27:293-299.
11. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker amelio-rates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287:E227-E232.
12. Li JS, Touyz RM, Schiffrin EL. Effects of AT1 and AT2 angiotensin receptors antagonists in angiotensin-infused rats. Hypertension 1998; 31:487-492.
13. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Lambert G, Friberg P. Increased sympathetic nerve activity in renovascular hypertension. Circulation 1999; 99:2537-2542.
14. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98:418-425.
15. Macari D, Whitebread S, Cumin F, De Gasparo M, Levens N. Renal actions of the angiotensin AT2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. Eur J Pharmacol 1994; 259:27-36.
16. Furukawa S, Hirano T, Mamo JC, Nagano S, Takahashi T. Catabolic defect of triglyceride is associated with abnormal very-low-density lipoprotein in experimental nephrosis. Metabolism 1990; 39:101-107.
17. Suga A, Hirano T, Inoue S, Tsuji M, Osaka T, Namba Y. Plasma leptin levels and triglyceride secretion rates in VMH-lesioned obese rats: a role of adiposity. Am J Physiol Endocrinol Metab 1999; 276:E650-E657.
18. Steiner G, Haynes FJ, Yoshino G, Vranic M. Hyperinsulinemia and in vivo very-low-density lipoprotein-triglyceride kinetics. Am J Physiol Endocrinol Metab 1984; 246:E187-E192.
19. Bird M, Williams MA, Baker N. Triacylglycerol secretion in rats: validation of a tracer method employing radioactive glycerol. J Nutr 1984; 114:1978-1985.
20. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Med Sci 1959; 37:911-917.
21. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23:201-229.
22. Chirieac DV, Chirieac LR, Corsetti JP, Cianci J, Sparks CE, Sparks JD. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab 2000; 279:E1003-E1011.
23. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003; 12:70-88.
24. Takagi T, Nakano Y, Takekoshi S, Inagami T, Tamura M. Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis. Carcinogenesis 2002; 23:1235-1241.
25. Blume A, Kaschina E, Unger T. Angiotensin II type 2 receptors: signaling and pathophysiological role. Curr Opin Nephrol Hypertens 2001; 10:239-246.
26. Kageyama A, Hirano T, Kageyama H, Oasaka T, Namba Y, Tsuji M. Distinct role of adiposity and insulin resistance in glucose intolerance: studies in ventromedial hypothalamic-lesioned obese rats. Metabolism 2002; 151:716-723.
27. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40:609-611.